Skip to content
Screener

Biohaven BHVN Total costs & expenses

Total costs & expenses at other companies

Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$165.48M+38.3%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$31.52M+63.2%
LON
LeonaBio, Inc.LONA
$17.21M+80.5%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.21B+46.6%
Enterprise value$2.22B+36.2%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:CostsAndExpenses.

The source filing: Biohaven’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001935979-26-000045
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Operating expenses:
Research and development$103,827$187,584
General and administrative26,60133,977
Total operating expenses130,428221,561
Loss from operations(130,428)(221,561)
Other income, net168493
Loss before provision for income taxes(130,260)(221,068)
Provision for income taxes272609

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Biohaven's total costs & expenses?
Biohaven (BHVN) reported total costs & expenses of $130.43M in Q1 2026.
How has Biohaven's total costs & expenses changed year-over-year?
Biohaven's total costs & expenses decreased by 41.1% year-over-year, from $221.56M to $130.43M.
What is the long-term trend for Biohaven's total costs & expenses?
Over 3 years (2022 to 2025), Biohaven's total costs & expenses has grown at a 9.5% compound annual growth rate (CAGR), from $567.93M to $745.38M.
What does total costs & expenses mean?
This metric represents the aggregate sum of all operating costs incurred by the company during a reporting period, including research and development, selling, general, and administrative expenses. It serves as a comprehensive measure of the capital required to sustain the company's clinical-stage operations and commercialization efforts. Monitoring this figure is essential for evaluating the company's burn rate and the efficiency of its investment in its drug development pipeline.

Ask your AI about Biohaven's total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude